Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles (Q38873430)

7 September 2017

title

Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles (English)

1 reference

7 September 2017

Keyu Li

1

1 reference

7 September 2017

Yaliang Lan

series ordinal

2

1 reference

7 September 2017

Jiabei Wang

series ordinal

3

1 reference

7 September 2017

Lianxin Liu

series ordinal

4

1 reference

7 September 2017

publication date

1 March 2017

1 reference

7 September 2017

1 reference

7 September 2017

volume

39

1 reference

7 September 2017

issue

3

1 reference

7 September 2017

page(s)

1010428317692229

1 reference

Sorafenib in advanced hepatocellular carcinoma

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Potentiality of immunotherapy against hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Adoptive T-cell therapy: a need for standard immune monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Genetically engineered T cells for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

TRUCKs: the fourth generation of CARs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Zoom Zoom: racing CARs for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

The in vitro antitumor effect and in vivo tumor-specificity distribution of human-mouse chimeric antibody against transferrin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Hepatocellualar carcinoma serum markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

The intraportal injection model for liver metastasis: advantages of associated bioluminescence to assess tumor growth and influences on tumor uptake of radiolabeled anti-carcinoembryonic antigen antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Anti-MUC1 nanobody can redirect T-body cytotoxic effector function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Tumor markers for hepatocellular carcinoma (Review)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Reversal of tumor immune inhibition using a chimeric cytokine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Collapse of the tumor stroma is triggered by IL-12 induction of Fas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

CD28z CARs and armored CARs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Antibody-modified T cells: CARs take the front seat for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Managing cytokine release syndrome associated with novel T cell-engaging therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Current concepts in the diagnosis and management of cytokine release syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

T-cell immunotherapy: looking forward

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Are natural killer cells superior CAR drivers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Modification of cytokine-induced killer cells with chimeric antigen receptors (CARs) enhances antitumor immunity to epidermal growth factor receptor (EGFR)-positive malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692229

21 January 2018

Identifiers

DOI

10.1177/1010428317692229

1 reference

7 September 2017

1 reference